Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020423 | 0.85 | HSD11B1 (0.74) | HSD11B1EPHX2L3MBTL1 | |
| SCHEMBL2020425 | 0.85 | HSD11B1 (0.74) | HSD11B1EPHX2L3MBTL1 | |
| SCHEMBL14159611 | 0.85 | HSD11B1 (0.73) | HSD11B1EPHX2 | |
| SCHEMBL3653957 | 0.81 | HSD11B1 (1.00) | HSD11B1L3MBTL1 | |
| SCHEMBL3620868 | 0.80 | HSD11B1 (1.00) | HSD11B1EPHX2L3MBTL1 | |
| SCHEMBL4685499 | 0.80 | HSD11B1 (0.97) | HSD11B1L3MBTL1 | |
| SCHEMBL3624059 | 0.79 | HSD11B1 (1.00) | HSD11B1EPHX2L3MBTL1 | |
| SCHEMBL3617559 | 0.75 | HSD11B1 (1.00) | HSD11B1L3MBTL1 | |
| SCHEMBL15310360 | 0.75 | EPHX2 (0.64) | HSD11B1EPHX2L3MBTL1 | |
| SCHEMBL3619951 | 0.74 | HSD11B1 (0.71) | HSD11B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | claimed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | claimed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | claimed |
| EP-2094263-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2009-09-02 | — | — | EP | claimed |
| WO-2008074384-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2008-06-26 | — | — | WO | claimed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011068927-A2 | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, CYP11B1 | HSD11B1 1/4885EPHX2 952/4885L3MBTL1 3653/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885EPHX2 661/4885L3MBTL1 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.